SAN DIEGO, June 8 /PRNewswire-FirstCall/ -- Dr. Steven Josephs, Ph.D., a former National Cancer Institute (NCI) researcher, has joined Entest BioMedical Inc.'s (www.entestbio.com) Science Advisory Board where he will focus on expanding the company’s stem cell cancer research. Dr. Josephs’ NCI research involved studies of the human T-cell leukemia virus, HIV and Human Herpervirus-6 genetic characterization. Josephs also worked for Baxter Healthcare and GenStar Therapeutics where he focused on the cellular and molecular biology of gene therapy for hemophilia. Entest BioMedical Inc. is a wholly-owned subsidiary of San Diego-based Bio-Matrix Scientific Group Inc. .
According to David Koos, Chairman and CEO of both Entest BioMedical Inc. and Bio-Matrix Scientific Group Inc., “Dr. Josephs’ extensive cancer research background adds strength to our growing Scientific Advisory Board. His insight into potential stem cell therapies for cancer patients will help expedite Entest BioMedical’s goal of providing innovative stem cell transplantation therapies and services including autologous and allogenic peripheral blood or bone marrow transplantation.
Dr. Feng Lin, Director of Research for Entest BioMedical and Bio-Matrix Scientific Group, also applauded the addition of Dr. Josephs’ to the Science Advisory Board. “Dr. Josephs joins our life science team at exactly the right time,” said Lin. “We’re currently interested in differentiating hematopoietic stem cells into immune cells especially T-cells. Dr. Josephs will work with us on our research goal of generating a new population of immune cells from a patient’s own stem cells to reactivate the patient’s immune system. This strategy represents a novel and effective immunotherapy especially for cancer patients and HIV patients who have injured immune systems and are at high risk of infection with bacteria and viruses.”
About Entest BioMedical Inc.:
Entest BioMedical, Inc., a wholly-owned subsidiary of Bio-Matrix Scientific Group, Inc. formed in April 2009, focuses on research and development of traumatic brain injury (TBI) and spinal cord injury using autologous ‘adipose-derived’ stem cells. Entest BioMedical is involved with R&D activities relating to stem cell therapies, diabetes testing and medical devices.
About Bio-Matrix Scientific Group Inc.:
Bio-Matrix Scientific Group Inc. is a San Diego, California based biotechnology research and development company with a 15,000 square foot facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories.
Disclaimer:
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT: David R. Koos, Chairman and CEO of Bio-Matrix Scientific Group
Inc., +1-619-702-1404, fax, +1-619-330-2328, info@BMSN.us; or
info@entestbio.com
Web site: http://www.BMSN.us/
http://www.entestbio.com/
